Innovent Presents the Results of the First Phase 3 Study of Mazdutide for Weight Management at the ADA’s 84th Scientific Sessions

SAN FRANCISCO and SUZHOU, China, June 24, 2024 /PRNewswire/ — Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks